Epitalon Estonia (Epithalamin): A Possibility for Anti-Aging
Epitalon (Epithalamin) is a peptide that has been researched and used for its anti-ageing properties. It has been demonstrated to be a powerful antioxidant on a par with melatonin and may impart benefits on longevity. Continue reading to learn more about Epitalon and its potential health risks.
Epitalon Estonia : What Is It?
Epitalon Estonia is indeed a synthetic peptide composed of four amino acids (aspartic acid, alanine, glutamic acid, and glycine) derived from the pineal gland peptide epithalamion. It was produced by Vladimir Khavinson, a Russian academic and gerontologist whose study centred on the development of peptide preparations for reversing and preventing the ageing process in several organs. He is currently the Director of the Institute of Bioregulation and Gerontology in Saint Petersburg.
Khavinson initially isolated Epithalamin from calves’ pineal glands. Due of the inherent limits of manufacture, he developed Epitalon, a synthetic version of the peptide.
Epitalon Is Used In What Ways?
Epitalon Estonia is typically delivered intravenously or intramuscularly, or transdermally (through the skin), because peptides are degraded in the digestive tract and hence unable to enter the bloodstream intact to exert their effects.
While some findings are encouraging, the majority of research has been conducted on animals and cells, leaving the potential health benefits and safety profile of Epitalon still unknown. Never take Epitalon without contacting your physician or as a substitute for medically approved therapy.
Inadequate Evidence for:
1) Pigmentosa Retinitis
Retinitis pigmentosa is a genetic degenerative eye disease that causes the rods in the retina to degenerate. Rods are one of two types of receptors found in the eye (the other is cones), which turn light into chemical signals that the brain can process.
Epitalon decreased degenerative damage to the retina caused by this syndrome in 90% of patients in a clinical trial.
Epitalon enhances retinal cell activity in rats by retaining their structure and preventing degeneration.
A single study involving humans and rats cannot be deemed sufficient data to establish Epitalon’s prospective application. Additional clinical trials are necessary to corroborate these early findings.
2) Circadian Rhythm Correction
Our circadian rhythms become more disrupted and subtle as we age, resulting in decreased melatonin output and altered sleep cycles.
Epithalamin increased melatonin synthesis and altered its cycle and peak concentrations to more closely mirror those of young people in a short experiment involving 14 elderly persons.
Epitalon peptide Estonia increased nighttime melatonin secretion and restored the circadian rhythm linked with cortisol release in elderly monkeys.
Again, this possible health advantage has been explored in only a tiny human trial and an animal study. Clinical trials on a larger scale and with greater rigour are necessary.
Animal and Cellular Research (Inadequate Evidence): There is insufficient clinical evidence to justify the use of Epitalon 10mg for any of the conditions described in this section. The following is a synopsis of current animal and cell-based research that should serve as a guide for future exploratory endeavours. The research cited, however, should not be taken as proof of any health advantage.
When given to fruit flies during their larval stage, the peptide enhanced their average longevity by 11-16 per cent.
Epitalon extended the maximum lifespan of rats subjected to equal quantities of light and darkness, varied amounts of darkness and light, or continuous light illumination by 68 days, 95 days, and 24 days, respectively, in contrast to controls.
Epitalon 100mg injections had no effect on the average longevity of mice with high blood pressure but did extend the peak lifespan by 12.3 per cent.
Epitalon Estonia was reported to boost telomerase activity in cell-based research. This enzyme increases the number of nucleotides in the protective regions at the ends of chromosomes (telomeres), enabling cells to divide and expand for an extended period of time.
Increasing the Activity of Enzymes
In aged adults, a reduction in pancreatic enzymes has been seen.
Epitalon boosted the activity of enzymes that digest protein and sugar in both young and old rats, with the effect being more pronounced in older rats.
Another study discovered that the peptide boosted enzyme activity in older rats’ small intestines.
The following section will address preliminary research on Epitalon’s anticancer activity. It is still in the animal stage, and additional clinical trials are needed to discover whether or if this peptide is useful in cancer therapy. Under no circumstances should Epitalon be used in place of traditional cancer therapy.
Epitalon boosted lymph flow (which contains white blood cells) and apoptosis (planned cell death) in rats with colon cancer, while also slowing tumour growth.
Epitalon Estonia significantly lowered the frequency of animals with multiple tumours and the maximum size of tumours in mice with mammary tumours when compared to control mice . Additionally, the researchers discovered that the peptide inhibited the expression of particular genes that, when over-activated, contribute significantly to the development of breast cancer in both mice and humans.
Another study in mice discovered that therapy with Epitalon significantly decreased the number of malignant tumours (cancerous tumours) and prevented cancer metastasizing (moving to another region in the body) in all treated mice. In comparison, metastases were identified in three of the nine mice that did not receive Epitalon therapy.